Department of Physical Therapy and University of Florida, Gainesville, Florida, USA.
McKnight Brain Institute, University of Florida, Gainesville, Florida, USA.
J Neurotrauma. 2021 Dec;38(24):3467-3482. doi: 10.1089/neu.2021.0301.
Respiratory compromise after cervical spinal cord injury (SCI) is a leading cause of mortality and morbidity. Most SCIs are incomplete, and spinal respiratory motoneurons as well as proprio- and bulbospinal synaptic pathways provide a neurological substrate to enhance respiratory output. Ampakines are allosteric modulators of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, which are prevalent on respiratory neurons. We hypothesized that low dose ampakine treatment could safely and effectively increase diaphragm electromyography (EMG) activity that has been impaired as a result of acute- or sub-acute cervical SCI. Diaphragm EMG was recorded using chronic indwelling electrodes in unanesthetized, freely moving rats. A spinal hemi-lesion was induced at C2 (C2Hx), and rats were studied at 4 and 14 days post-injury during room air breathing and acute respiratory challenge accomplished by inspiring a 10% O, 7% CO gas mixture. Once a stable baseline recording was established, one of two different ampakines (CX717 or CX1739, 5 mg/kg, intravenous) or a vehicle (2-hydroxypropyl-beta-cyclodextrin [HPCD]) was delivered. At 4 days post-injury, both ampakines increased diaphragm EMG output ipsilateral to C2Hx during both baseline breathing and acute respiratory challenge. Only CX1739 treatment also led to a sustained (15 min) increase in ipsilateral EMG output. At 14 days post-injury, both ampakines produced sustained increases in ipsilateral diaphragm EMG output and enabled increased output during the respiratory challenge. We conclude that low dose ampakine treatment can increase diaphragm EMG activity after cervical SCI, and therefore may provide a pharmacological strategy that could be useful in the context of respiratory rehabilitation.
颈椎脊髓损伤(SCI)后呼吸功能障碍是导致发病率和死亡率的主要原因。大多数 SCI 是不完全的,脊髓呼吸运动神经元以及本体感觉和球海绵体突触通路为增强呼吸输出提供了神经基础。Ampakines 是 α-氨基-3-羟基-5-甲基-4-异恶唑丙酸(AMPA)受体的别构调节剂,在呼吸神经元上普遍存在。我们假设低剂量的 Ampakine 治疗可以安全有效地增加由于急性或亚急性颈椎 SCI 而受损的膈肌肌电图(EMG)活动。在未麻醉、自由活动的大鼠中,使用慢性留置电极记录膈肌 EMG。在 C2 处诱导半脊髓损伤(C2Hx),并在损伤后 4 天和 14 天在室内空气呼吸和通过吸入 10%O、7%CO 混合气进行急性呼吸挑战期间研究大鼠。一旦建立了稳定的基线记录,就会给予两种不同的 Ampakine(CX717 或 CX1739,5mg/kg,静脉内)之一或载体(2-羟丙基-β-环糊精[HPCD])。在损伤后 4 天,两种 Ampakine 均在基线呼吸和急性呼吸挑战期间增加了 C2Hx 同侧的膈肌 EMG 输出。只有 CX1739 治疗还导致同侧 EMG 输出持续(15 分钟)增加。在损伤后 14 天,两种 Ampakine 均导致同侧膈肌 EMG 输出持续增加,并使呼吸挑战期间的输出增加。我们得出结论,低剂量 Ampakine 治疗可以增加颈椎 SCI 后的膈肌 EMG 活动,因此可能提供一种在呼吸康复方面有用的药理学策略。